Therapeutic Options for NSCLC with Rare Mutations

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Results from the phase 3 MARIPOSA trial found that amivantamab plus lazertinib met the final pre-specified secondary end point of overall survival in NSCLC.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Findings from the phase 3 SACHI trial support the National Medical Products Administration’s priority review designation for savolitinib/osimertinib.

Although not hitting its primary end point, a phase 2 trial showed that SBRT plus concurrent radiotherapy improved on results elicited in other trials.